Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis by Dijkhorst P.J. (20584910)

Mutations decreasing complexity are more frequent than mutations increasing it. by Pascal F. Hagolani (10189866)

Over time, melanization decreases with aging, higher temperature, and infection. by Lindsay E. Martin (17377067)

PKCλ KD leads to decreases in CD133-positive cells. by Yuka Nozaki (9115620)

FTY720 treatment decreased phosphorylation of AKT, ERK, and c-myc. by Laura L. Stafman (6577184)

Subjects:

FTA card stabilization of YFV RNA decrease at high temperature. by Emily H. Davis (12878086)

Novel surfactant lipids decreased in COPD correlating with FEV1. by Christina W. Agudelo (8415171)

Drug-induced decrease of cell anisotropy reduces pattern fidelity. by Camille Curantz (7456499)

“…<b>(B)</b> Quantifications of primordia spacing variability on phalloïdin-stained control flat skins (explant; triangles) and LatA-treated cultured explants (+LatA; squares) of Japanese quail embryos showed that LatA treatment caused a significant decrease in pattern fidelity at condensation stage (explants, <i>n</i> = 9; +LatA, <i>n</i> = 9; unpaired 2-tailed <i>t</i> test; <i>p</i> = 0.0233) and differentiation stage (explants, <i>n</i> = 8; +LatA, <i>n</i> = 9; <i>p</i> = 0.002). …”

Structure of a trial. by Marcel F. Hinss (14675457)

“…While learning effects may have negated the impact of mental fatigue across the 5 experimental blocks, a significant decrease in performance was observed within blocks. …”

Damage accumulation decreases elongation rates and displaces growth equilibrium. by Audrey Menegaz Proenca (845486)

“…<p>All panels depict MG1655 wild-type <i>E</i>. <i>coli</i>. (A) Exposure to phototoxic damage led to decreasing elongation rates in all treatment levels (length of exposure, every 2 min: 70 ms, 700 ms, 1 s, 1.5 s, 3 s). …”

K2 treatment renders <i>K</i>. <i>pneumoniae</i> more susceptible to intracellular killing. by Estelle Ifrid (10076719)

Subjects:

Selected compounds exhibit no antibiotic activity against <i>K</i>. <i>pneumoniae</i>. by Estelle Ifrid (10076719)

Subjects:

Three compounds affect the interaction between <i>K</i>. <i>pneumoniae</i> and phagocytic amoebae. by Estelle Ifrid (10076719)

Subjects:

Intracellular killing of <i>K</i>. <i>pneumoniae</i> mutants. by Estelle Ifrid (10076719)

Subjects:

K2 increases intracellular killing of <i>K</i>. <i>pneumoniae</i> by <i>kil1</i> KO and <i>kil2</i> KO cells. by Estelle Ifrid (10076719)

Subjects:

S1 Data - by Estelle Ifrid (10076719)

Subjects:

K2 treatment does not visibly affect LPS structure. by Estelle Ifrid (10076719)

Subjects:

K2 increases the intracellular killing of <i>K</i>. <i>pneumoniae</i> by <i>phg1a KO</i> cells. by Estelle Ifrid (10076719)

Subjects:

K2 treatment increases access of a hydrophobic probe to the bacterial membrane of <i>K</i>. <i>pneumoniae</i>. by Estelle Ifrid (10076719)

Subjects:

K2 increases the sensitivity of <i>K</i>. <i>pneumoniae</i> to polymyxin B. by Estelle Ifrid (10076719)

Subjects: